Table 4 Open in new tab Adverse events...

Flecainide (n = 22)

Sotalol >160 mg per day (n = 37)

Amiodarone (n = 57)

Dronedarone (n = 3)

Max dose (mg/day)

173 ± 46

258 ± 37

547 ± 144

800 ± 0

Duration of use (days)

146 (31–315)

58 (24–259)

273 (158–351)

21 (17–42)

Total adverse events

3 (13.6%)^a

9 (24.3%)^a

14 (24.6%)^a

1 (33.3%)^a

Cardiovascular complications

2 (1)^b

8 (7)

–

1 (1)

Fatigue

2 (1)

3 (3)

–

Bradycardia

–

2 (2)

–

1 (1)

Hypotension + dizziness

–

2 (2)

–

Cold extremities

–

1 (0)

–

Dermatological complications

–

5 (1)

–

Thyroid dysfunction

–

5 (0)

–

Subclinical hypothyroidism

–

3 (0)

Hypothyroidism

–

1 (0)

Latent hyperthyroidism

–

1 (0)

Ophthalmic complications

–

3 (2)

–

Blurred vision

–

2 (2)

Cornea deposit

–

1 (0)

Neurological problems

–

1 (1)

–

Tinnitus

1 (1)

Pulmonary complications

–

1 (1)

–

Pneumonitis

1 (1)

Gastrointestinal complications

1 (0)

–

Diarrhoea

1 (0)

AAD stopped due to AEs

1 (4.5%)

8 (21.6%)

4 (7.0%)

1 (33.3%)

AAD stopped due to AF recurrences

7 (31.8%)

16 (43.2%)

11 (19.3%)

2 (66.7%)

AAD stopped due to long-term sinus rhythm maintenance

1 (4.5%)

4 (10.8%)

4 (7.0%)

0 (0.0%)

AAD continued during follow-up

13 (59.1%)

9 (24.3%)

38 (66.7%)

0 (0.0%)

Table 4

Open in new tab

Adverse events associated with antiarrhythmic drugs and reasons for discontinuation

	Flecainide (n = 22)	Sotalol >160 mg per day (n = 37)	Amiodarone (n = 57)	Dronedarone (n = 3)
Max dose (mg/day)	173 ± 46	258 ± 37	547 ± 144	800 ± 0
Duration of use (days)	146 (31–315)	58 (24–259)	273 (158–351)	21 (17–42)
Total adverse events	3 (13.6%)^a	9 (24.3%)^a	14 (24.6%)^a	1 (33.3%)^a
Cardiovascular complications	2 (1)^b	8 (7)	–	1 (1)
Fatigue	2 (1)	3 (3)	–	–
Bradycardia	–	2 (2)	–	1 (1)
Hypotension + dizziness	–	2 (2)	–	–
Cold extremities	–	1 (0)	–	–
Dermatological complications	–	–	5 (1)	–
Thyroid dysfunction	–	–	5 (0)	–
Subclinical hypothyroidism	–	–	3 (0)
Hypothyroidism	–	–	1 (0)
Latent hyperthyroidism	–	–	1 (0)
Ophthalmic complications	–	–	3 (2)	–
Blurred vision	–	–	2 (2)
Cornea deposit	–	–	1 (0)
Neurological problems	–	1 (1)	–	–
Tinnitus		1 (1)
Pulmonary complications	–	–	1 (1)	–
Pneumonitis			1 (1)
Gastrointestinal complications	1 (0)	–	–	–
Diarrhoea	1 (0)
AAD stopped due to AEs	1 (4.5%)	8 (21.6%)	4 (7.0%)	1 (33.3%)
AAD stopped due to AF recurrences	7 (31.8%)	16 (43.2%)	11 (19.3%)	2 (66.7%)
AAD stopped due to long-term sinus rhythm maintenance	1 (4.5%)	4 (10.8%)	4 (7.0%)	0 (0.0%)
AAD continued during follow-up	13 (59.1%)	9 (24.3%)	38 (66.7%)	0 (0.0%)

	Flecainide (n = 22)	Sotalol >160 mg per day (n = 37)	Amiodarone (n = 57)	Dronedarone (n = 3)
Max dose (mg/day)	173 ± 46	258 ± 37	547 ± 144	800 ± 0
Duration of use (days)	146 (31–315)	58 (24–259)	273 (158–351)	21 (17–42)
Total adverse events	3 (13.6%)^a	9 (24.3%)^a	14 (24.6%)^a	1 (33.3%)^a
Cardiovascular complications	2 (1)^b	8 (7)	–	1 (1)
Fatigue	2 (1)	3 (3)	–	–
Bradycardia	–	2 (2)	–	1 (1)
Hypotension + dizziness	–	2 (2)	–	–
Cold extremities	–	1 (0)	–	–
Dermatological complications	–	–	5 (1)	–
Thyroid dysfunction	–	–	5 (0)	–
Subclinical hypothyroidism	–	–	3 (0)
Hypothyroidism	–	–	1 (0)
Latent hyperthyroidism	–	–	1 (0)
Ophthalmic complications	–	–	3 (2)	–
Blurred vision	–	–	2 (2)
Cornea deposit	–	–	1 (0)
Neurological problems	–	1 (1)	–	–
Tinnitus		1 (1)
Pulmonary complications	–	–	1 (1)	–
Pneumonitis			1 (1)
Gastrointestinal complications	1 (0)	–	–	–
Diarrhoea	1 (0)
AAD stopped due to AEs	1 (4.5%)	8 (21.6%)	4 (7.0%)	1 (33.3%)
AAD stopped due to AF recurrences	7 (31.8%)	16 (43.2%)	11 (19.3%)	2 (66.7%)
AAD stopped due to long-term sinus rhythm maintenance	1 (4.5%)	4 (10.8%)	4 (7.0%)	0 (0.0%)
AAD continued during follow-up	13 (59.1%)	9 (24.3%)	38 (66.7%)	0 (0.0%)

AAD, antiarrhythmic drug; AE, adverse event; AF, atrial fibrillation.

None was life-threatening or required emergency hospital admission.

Number between brackets represents number of cases that the adverse event led to discontinuation of AAD.

This Feature Is Available To Subscribers Only